Toll Free: 1-888-928-9744
Published: Feb, 2017 | Pages:
189 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2017, provides an overview of the Systemic Sclerosis (Scleroderma) (Immunology) pipeline landscape. Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 12, 4, 22 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively. Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma) (Immunology). - The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Systemic Sclerosis (Scleroderma) (Immunology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Systemic Sclerosis (Scleroderma) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) (Immunology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 7 Global Markets Direct Report Coverage 7 Systemic Sclerosis (Scleroderma) - Overview 8 Systemic Sclerosis (Scleroderma) - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 14 Products under Development by Companies 15 Products under Development by Universities/Institutes 18 Systemic Sclerosis (Scleroderma) - Therapeutics Assessment 19 Assessment by Target 19 Assessment by Mechanism of Action 23 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development 31 Allergan Plc 31 AnaMar AB 31 Angion Biomedica Corp 32 arGentis Pharmaceuticals LLC 32 Bayer AG 33 Biogen Inc 33 BiOrion Technologies BV 34 BLR Bio LLC 34 Boehringer Ingelheim GmbH 35 Bristol-Myers Squibb Company 35 Covis Pharmaceuticals Inc 36 CSL Ltd 36 Cumberland Pharmaceuticals Inc 37 F. Hoffmann-La Roche Ltd 37 Fibrocell Science Inc 38 GenKyoTex SA 38 Gilead Sciences Inc 39 GlaxoSmithKline Plc 39 iBio Inc 40 Inventiva 40 Kadmon Corp LLC 41 MedImmune LLC 41 miRagen Therapeutics Inc 42 Patagonia Pharmaceuticals LLC 42 PDX Pharmaceuticals LLC 43 Peptinov SAS 43 ProMetic Life Sciences Inc 44 Ribomic Inc 44 Samumed LLC 45 Sanofi 45 Stemline Therapeutics Inc 46 viDA Therapeutics Inc 46 VivaCell Biotechnology Espana SL 47 Systemic Sclerosis (Scleroderma) - Drug Profiles 48 abatacept - Drug Profile 48 acALY-18 - Drug Profile 55 ambrisentan - Drug Profile 56 ANG-3070 - Drug Profile 58 ARG-201 - Drug Profile 59 belimumab - Drug Profile 61 BLR-200 - Drug Profile 68 BOT-191 - Drug Profile 69 C-1889 - Drug Profile 70 C-82 - Drug Profile 72 CM-101 - Drug Profile 73 dimethyl fumarate DR - Drug Profile 74 factor XIII (human) - Drug Profile 79 FCX-013 - Drug Profile 80 GKT-831 - Drug Profile 81 GSK-2330811 - Drug Profile 84 IBIOCFB-03 - Drug Profile 85 ifetroban sodium - Drug Profile 87 IVA-337 - Drug Profile 89 JBT-101 - Drug Profile 91 KD-025 - Drug Profile 97 M-10 - Drug Profile 102 MEDI-7734 - Drug Profile 103 miRNA-29 - Drug Profile 104 Monoclonal Antibodies to Antagonize IL-3RA for Autoimmune Disorders - Drug Profile 105 MRG-201 - Drug Profile 106 nintedanib - Drug Profile 108 nitroglycerin - Drug Profile 119 onabotulinumtoxinA - Drug Profile 121 PAT-048 - Drug Profile 126 PATS-03 - Drug Profile 127 PBI-4050 - Drug Profile 128 PDX-002 - Drug Profile 135 PPV-06 - Drug Profile 136 RBM-006 - Drug Profile 137 riociguat - Drug Profile 138 rituximab biosimilar - Drug Profile 144 RP-182 - Drug Profile 145 SAR-100842 - Drug Profile 146 SAR-156597 - Drug Profile 147 SAR-317461 - Drug Profile 148 SM-04755 - Drug Profile 149 Small Molecule to Inhibit NFkB for Autoimmune Disorders, Melanoma and Inflammation - Drug Profile 150 Small Molecules to Antagonize 5-HT2B for Fibrosis - Drug Profile 151 Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - Drug Profile 152 terguride - Drug Profile 153 tocilizumab - Drug Profile 154 TRX-101 - Drug Profile 164 VCE-0048 - Drug Profile 165 VEDA-1209 - Drug Profile 166 VTI-1000 Series - Drug Profile 167 Wnt-001 - Drug Profile 168 Systemic Sclerosis (Scleroderma) - Dormant Projects 169 Systemic Sclerosis (Scleroderma) - Discontinued Products 171 Systemic Sclerosis (Scleroderma) - Product Development Milestones 172 Featured News & Press Releases 172 Appendix 185 Methodology 185 Coverage 185 Secondary Research 185 Primary Research 185 Expert Panel Validation 185 Contact Us 185 Disclaimer 186
List of Tables
Number of Products under Development for Systemic Sclerosis (Scleroderma), H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Allergan Plc, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by AnaMar AB, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Angion Biomedica Corp, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by arGentis Pharmaceuticals LLC, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Bayer AG, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Biogen Inc, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by BiOrion Technologies BV, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by BLR Bio LLC, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Boehringer Ingelheim GmbH, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Bristol-Myers Squibb Company, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Covis Pharmaceuticals Inc, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by CSL Ltd, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Cumberland Pharmaceuticals Inc, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Fibrocell Science Inc, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by GenKyoTex SA, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Gilead Sciences Inc, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by GlaxoSmithKline Plc, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by iBio Inc, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Inventiva, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Kadmon Corp LLC, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by MedImmune LLC, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by miRagen Therapeutics Inc, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Patagonia Pharmaceuticals LLC, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by PDX Pharmaceuticals LLC, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Peptinov SAS, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by ProMetic Life Sciences Inc, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Ribomic Inc, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Samumed LLC, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Sanofi, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Stemline Therapeutics Inc, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by viDA Therapeutics Inc, H1 2017 Systemic Sclerosis (Scleroderma) - Pipeline by VivaCell Biotechnology Espana SL, H1 2017 Systemic Sclerosis (Scleroderma) - Dormant Projects, H1 2017 Systemic Sclerosis (Scleroderma) - Dormant Projects, H1 2017 (Contd..1), H1 2017 Systemic Sclerosis (Scleroderma) - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.